A good medical weight-loss program has three things: a licensed clinician who evaluates you before prescribing anything, real follow-up that adjusts treatment over months, and pricing you can read without a sales call. Everything else, including whether the clinic is down the street or on a screen, is secondary. When people search “weight loss near me,” the nearest option is not automatically the best one, and the flashiest one rarely is.
What makes a program medical rather than commercial?
The dividing line is clinical accountability. A medical program means a physician, nurse practitioner, or physician assistant assesses your history, orders labs when warranted, and takes responsibility for the plan over time. A commercial program sells a diet, a shake, or a coaching subscription, and no one is answerable for a medical outcome.
This matters because obesity is now defined clinically, not by appearance or willpower. A 2025 effort to set diagnostic criteria for clinical obesity, published in The Lancet Diabetes and Endocrinology (definition and diagnostic criteria of clinical obesity), pushed the field toward treating it as a chronic disease with organ-level effects rather than a cosmetic problem. A program that treats it as anything less is behind current practice.
Who should be doing the prescribing?
Ask directly who writes the prescription and whether that person will still be involved at month three. The answer should be a named, licensed clinician, not “our medical team” as an abstraction. Prescribing a GLP-1 medication is not a rubber stamp. It involves screening for contraindications, choosing a starting dose, and planning the titration schedule that the Wegovy prescribing information lays out over several months.
Current guidance backs this up. The 2025 clinical practice guideline update on pharmacotherapy for obesity management in adults and the earlier AGA Clinical Practice Guideline on pharmacological interventions both frame medication as one component of ongoing care, prescribed and monitored by a clinician, not a product handed over at intake.
How do in-person clinics and telehealth actually compare?
| Factor | Local in-person clinic | Telehealth program |
|---|---|---|
| Labs and exams | Often done on site | Ordered locally or through a partner lab |
| Scheduling | Fixed office hours, travel time | Flexible, often same week |
| Continuity | Same clinician if the practice is small | Depends on the platform’s model |
| Medication options | Branded, sometimes compounded | Branded, self-pay, or compounded |
| Best fit | People wanting hands-on care in one place | People valuing flexibility and speed |
Format is a preference, not a quality marker. A well-run telehealth program with monthly check-ins beats a nearby clinic that sees you once and mails refills. The reverse is also true. Judge the care, then let geography and convenience break the tie.
What does adequate follow-up look like?
During the first few months, dosing steps up on a schedule, and side effects like nausea are most common early. That is exactly when contact should be frequent, at least monthly, with a clear way to reach someone between visits. A program that writes a full-dose prescription at the first appointment and offers no structured follow-up is not managing a chronic condition.
The trial evidence explains why continuity is the whole point. In the STEP 3 trial, semaglutide paired with intensive behavioral therapy produced larger weight loss than medication alone, which tells you the counseling around the drug is part of the treatment. The STEP 4 trial showed that people who stopped the medication regained weight, and the STEP 1 trial extension confirmed most lost weight returned within a year of withdrawal. A program with no plan for the long term is setting you up for that rebound.
Should the choice of medication drive the choice of program?
Not usually. The better question is whether the program can offer more than one option and explain the trade-offs. The STEP 8 trial compared weekly semaglutide against daily liraglutide and found larger average weight loss with semaglutide, which is useful context, though it is not a stand-in for a decision made with a clinician who knows your history and other conditions.
That history matters more than marketing suggests. Someone with fatty liver disease, for instance, may have added reasons to consider these drugs; the EASL-EASD-EASO guidelines on MASLD discuss metabolic benefits that reach beyond the scale. A program that asks about your full medical picture is doing its job. One that offers a single product to everyone who walks in is selling, not treating.
How should pricing and access be presented?
Honest programs publish what things cost and explain the routes: insurance coverage where the plan covers obesity medication, manufacturer self-pay for branded drugs, and compounded options. Compounded semaglutide and tirzepatide deserve a plain statement of fact. They are prepared by compounding pharmacies, they are not FDA-approved products, and they have not been through the approval process that generated the trial data above. Some people choose them for predictable cash pricing, but that trade should be discussed with the prescriber, not buried in fine print.
If you want to compare named options side by side, several run legitimate physician-supervised care, including Ro, Hims and Hers, Henry Meds, LillyDirect, and NovoCare. For sorting local in-person practices against remote ones, the FormBlends provider directory is one place to check which clinics and supervised telehealth options serve a given area before you book anything. Whatever the source, insist on a written price and a clear refill and follow-up policy before you pay.
What are the clearest red flags?
Watch for pressure to buy a long package before any evaluation, vague answers about who prescribes, guarantees of a specific pound count, and refusal to order or review labs. Weight loss is individual, and no honest clinician promises a number. A program that treats the first no from your insurer as final, rather than helping with an appeal, is also cutting a corner that costs you money.
Key takeaways
- A named licensed clinician should evaluate you and stay involved past the first visit.
- Follow-up at least monthly during titration is a marker of real care, not an upsell.
- In-person and telehealth are both fine; care quality outranks format and distance.
- Compounded drugs are not FDA-approved; that fact belongs in the open, not the fine print.
- Published, readable pricing and a clear refill policy separate treatment from a sales pitch.
See also: A Practical Guide to Financial Statement Preparation for Growing Businesses
Frequently asked questions
What actually makes a weight-loss program medical rather than commercial?
A licensed clinician evaluates the person, can prescribe when appropriate, and manages the case over time. A commercial plan sells a diet or a coaching subscription without that clinical accountability.
Is an in-person clinic better than telehealth for this?
Neither is better by default. In-person care suits people who want labs and physical exams under one roof. Telehealth suits people who value scheduling flexibility. The prescriber quality and follow-up matter more than the format.
How much follow-up should a good program include?
Enough to adjust the dose, check side effects, and track progress at least monthly during titration. Programs that write one prescription and disappear are not managing a chronic condition.
Are compounded weight-loss medications the same as the branded ones?
No. Compounded semaglutide and tirzepatide are prepared by compounding pharmacies and are not FDA-approved products. They may share the active molecule but have not gone through the approval process behind the trial evidence.
What is the biggest red flag in a local program?
Pressure to commit to a long paid package before any clinical evaluation, paired with vague answers about who prescribes and how refills and follow-up work.
